UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
not accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Hereditary gastrointestinal polyposis syndromes

Luigi Ricciardiello

Summary

AI Generated

An online course on hereditary gastrointestinal polyposis syndromes covers genetic basis, presentation, cancer risk, diagnosis, screening, surveillance, and treatment options for these rare diseases that carry significant colorectal and other cancer risks.

  • Hereditary gastrointestinal polyposis syndromes are rare diseases that confer a significant risk of colorectal and other cancers
  • Correct diagnosis is needed to ensure patients undergo appropriate screening and follow-up for cancer prevention and to ascertain risk in family members
  • Multidisciplinary management is essential and the involvement of a clinical geneticist is mandatory
  • The course covers genetic basis, presentation, extracolonic features, cancer risk, diagnosis, screening, surveillance, and treatment options for the various types of hereditary gastrointestinal polyposis syndrome
  • The course is suitable for gastroenterologists in training, physicians and surgeons in other disciplines, nurses, biotechnicians, and advanced-years medical students with an interest in gastroenterology
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Hereditary gastrointestinal polyposis syndromes are rare diseases that confer a significant risk of colorectal and other cancers. Correct diagnosis is needed to ensure patients undergo appropriate screening and follow-up for cancer prevention, and to ascertain risk in family members. Multidisciplinary management is essential to ensure appropriate clinical choices are made, and the involvement of a clinical geneticist is mandatory.

This online course addresses the various types of hereditary gastrointestinal polyposis syndrome. The genetic basis of each syndrome is considered, along with their presentation, extracolonic features, cancer risk, diagnosis, screening, surveillance and treatment options.

Learning objectives

 

  • To become familiar with hereditary gastrointestinal polyposis syndromes
  • To correctly diagnose hereditary gastrointestinal polyposis syndromes
  • To appropriately manage hereditary gastrointestinal polyposis syndromes

Target audience

This course is suitable for gastroenterologists in training and physicians and surgeons in other disciplines, as well as nurses, biotechnicians and advanced-years’ medical students who have an interest in gastroenterology. 

Event

Hereditary gastrointestinal polyposis syndromes

Topics

Digestive Oncology

Accreditation status

not accredited

Duration

1 hour

Published

2018

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

Bruce E. Sands 1, Marla C. Dubinsky 2, Alessandro Armuzzi 3,4, Christopher Ma 5,6, Irina Blumenstein 7, Anita Afzali 8, Patryk Smolinski 9, Martina Goetsch 10, Krisztina Lazin 10, Michael Keating 11, Maria Kudela 12, Chuanbo Zang 13, Michelle Segovia 11, Diogo Branquinho 11, John C. Woolcott 13, Silvio Danese 14, David T. Rubin 15

Affiliations

1 Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States

2 Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States

3 IBD Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

4 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

5 Division of Gastroenterology and Hepatology, University of Caglary, Calgary, AB, Canada

6 Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada

7 Goethe University Frankfurt, Frankfurt University Hospital, Medical Clinic 1, Frankfurt am Main, Germany

8 Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, United States

9 Penta Hospitals Przychodnie, Wrocław Wejherowskam, Poland

10 Pfizer AG, Zürich, Switzerland

11 Pfizer Inc, New York, NY, United States

12 Pfizer Inc, Cambridge, MA, United States

13 Pfizer Inc, Collegeville, PA, United States

14 Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy

15 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate receptor modulator for the treatment of ulcerative colitis (UC). Cumulative safety data of up to 5 years of etrasimod exposure in the global UC clinical programme have been reported.1

Aims & Methods

We present the long-term efficacy of etrasimod 2 mg QD through 2 years in the ongoing ELEVATE UC open‑label extension (OLE) study (NCT03950232), stratified by prior biologic/Janus kinase inhibitor (bio/JAKi) exposure. The OLE enrolled patients from five parent studies. Efficacy endpoints were evaluated at Weeks 52 and 104 of the OLE, and included clinical remission, clinical response, endoscopic improvement, symptomatic response and symptomatic remission. Endpoints were assessed among bio/JAKi-naïve and -experienced patients (as defined at parent study baseline) who entered the OLE as clinical responders (data cut-off: 20 June 2024). Data are reported using observed cases with corresponding modified nonresponder imputation (NRI) rates.

Results

​Data from 390 etrasimod-treated patients were included (bio/JAKi naïve: N=287; bio/JAKi experienced: N=103). Among bio/JAKi-naïve patients, at Weeks 52 and 104 of the OLE, respectively, clinical response rates were 90.4% (NRI: 76.7%) and 87.1% (63.9%), clinical remission rates were 55.8% (47.3%) and 52.7% (38.7%), endoscopic improvement rates were 63.9% (53.7%) and 63.3% (45.3%), symptomatic response rates were 96.6% (79.9%) and 95.4% (68.2%) and symptomatic remission rates were 82.5% (68.2%) and 76.0% (54.4%). Results were similar among bio/JAKi-experienced patients (Table); at Weeks 52 and 104 of the OLE, respectively, clinical remission rates were 57.7% (43.7%) and 55.0% (33.0%) and endoscopic improvement rates were 67.6% (46.6%) and 64.8% (35.0%).

Table. Efficacy of etrasimod 2 mg QD at Weeks 52 and 104 of ELEVATE UC OLE among clinical responders in parent studies (N=390)a
Efficacy endpoints
% (n/N)
Bio/JAKi naïve (N=287)
Bio/JAKi experienced (N=103)
OLE Week 52
OLE Week 104
OLE Week 52
OLE Week 104
Observed
NRIb
Observed
NRIb
Observed
NRIb
Observed
NRIb
Clinical responsec
90.4 (217/240)
76.7 (217/283)
87.1 (175/201)
63.9 (175/274)
83.3 (65/78)
63.1 (65/103)
83.3 (50/60)
50.0 (50/100)
Clinical remissiond
55.8 (134/240)
47.3 (134/283)
52.7 (106/201)
38.7 (106/274)
57.7 (45/78)
43.7 (45/103)
55.0 (33/60)
33.0 (33/100)
Endoscopic improvemente
63.9 (152/238)
53.7 (152/283)
63.3 (124/196)
45.3 (124/274)
67.6 (48/71)
46.6 (48/103)
64.8 (35/54)
35.0 (35/100)
Symptomatic responsef
96.6 (226/234)
79.9 (226/283)
95.4 (187/196)
68.2 (187/274)
92.3 (72/78)
69.9 (72/103)
94.9 (56/59)
56.0 (56/100)
Symptomatic remissiong
82.5 (193/234)
68.2 (193/283)
76.0 (149/196)
54.4 (149/274)
82.1 (64/78)
62.1 (64/103)
84.7 (50/59)
50.0 (50/100)
aEfficacy was assessed among clinical responders to etrasimod 1 mg, 2 mg or placebo QD at the last visit of the parent study prior to OLE entry.
bNRI includes in the denominator those patients who had reached the corresponding time point and those who withdrew before the time point but would have reached the time point if they had stayed. Patients with missing data were treated as nonresponders.
cClinical response was defined as a ≥2-point and ≥30% decrease from parent study baseline in MMS and a ≥1-point decrease from parent study baseline in RBS or absolute RBS ≤1.
dClinical remission was defined as SFS=0 (or =1 with a ≥1-point decrease from parent study baseline), RBS=0 and ES ≤1 (excluding friability).
eEndoscopic improvement was defined as ES ≤1.
fSymptomatic response was defined as a ≥30% decrease from parent study baseline in composite RBS and SFS.
gSymptomatic remission was defined as SFS=0 (or =1 with a ≥1-point decrease from parent study baseline) and RBS=0.
bio/JAKi, biologic/Janus kinase inhibitor; ES, endoscopic subscore; MMS, modified Mayo score; N, number of patients in subgroup; n, number of patients; NRI, modified nonresponder imputation; OLE, open-label extension; QD, once daily; RBS, rectal bleeding subscore; SFS, stool frequency subscore; UC, ulcerative colitis.

Conclusion

Etrasimod demonstrated durable efficacy through 2 years of treatment in the OLE across clinical, endoscopic and symptomatic outcomes in patients with active UC with and without prior bio/JAKi exposure. This study is ongoing with future data readouts expected.

References

1. Rubin DT et al. J Crohns Colitis 2026; 20: i2593–i2595.
Pfizer’s generative artificial intelligence tool MAIA was used to assist production of the abstract first draft. Authors reviewed/edited and take responsibility for the content.

Disclosure

BES consulting fees: Aclaris Therapeutics, Adaxion Therapeutics, Adiso Therapeutics, Agomab Therapeutics, Alfasigma, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Attovia Therapeutics, Biolojic Design, BiomeBank, Biora Therapeutics, Boehringer-Ingelheim, Caldera Therapeutics, Cellarity, Cytoki Pharma, Disc Medicine, Eli Lilly, Ensho Therapeutics, Enthera, Enveda Biosciences, Equillium, Evommune, Ferring, Fzata, Galapagos, Genentech (Roche), Genesis Therapeutics, Gilead Sciences, GlaxoSmithKline, Globalport, Ignite Biomedical, Imedex, Imhotex, Immunitas Therapeutics, Immunyx Pharma, Kallyope, Kyowa Kirin, LifeMine Therapeutics, Merck, MSD, Microba, Microbiotica, Mirador Therapeutics, Mitsubishi Tanabe Pharma, Mobius Care, Morphic Therapeutic, MRM Health, Nexus Therapeutics, Nimbus Discovery, Novartis, Numab Therapeutics, Odyssey Therapeutics, ONO Pharmaceutical, OSE Immunotherapeutics, Palisade Bio, Pioneering Medicines Explorations, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Quotient Therapeutics, Rasayana Therapeutics, Recludix Pharma, Reistone Biopharma, Sanofi, Slate Bio, Sorriso Pharmaceuticals, Spyre Therapeutics, Synlogic, Target RWE, Telavant, Teva, Thetis Pharmaceuticals, Tr1X, TRexBio, Union Therapeutics, VectivBio, Vedanta Biosciences, Vividion Therapeutics, Xencor; Consulting/speaker fees/other support: AbbVie, Abivax, Bristol Myers Squibb, Celltrion, Eli Lilly, Genentech (Roche), Johnson & Johnson Innovative Medicine/Janssen, Merck, Pfizer Inc, Takeda, Teva; Consulting fees/stock/stock options: Ventyx Biopharma; Stock options: Caldera Therapeutics, Mirador Therapeutics; Stock: Doximity.
MCD consulting fees: AbbVie, Abivax, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Lilly, Galapagos, Genentech, Gilead Sciences, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Pfizer Inc, Prometheus Biosciences, Prometheus Laboratories, Sanofi, Sphyre, Takeda, UCB.
AAr consulting fees: AbbVie, Abivax, AlfaSigma, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Lilly, Enthera Pharmaceuticals, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Giuliani, Janssen, Lionhealth, MSD, Nestlé, Pfizer Inc, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, Sanofi, Takeda, Teva Pharmaceuticals and Tillotts Pharma; grant/research support: Biogen, MSD, Pfizer Inc, Takeda; lecture/speaker fees: AbbVie, Abivax, AG Pharma, AlfaSigma, Biogen, Bristol Myers Squibb, Celltrion, Lilly, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Gilead Sciences, Janssen, Lionhealth, MSD, Novartis, Pfizer Inc, Roche, Samsung Bioepis, Sandoz, Takeda, Teva Pharmaceuticals.
CM  consulting fees: AbbVie, Alimentiv, Amgen, Anaptys Bio, AVIR Pharma Inc, Bristol Myers Squibb, Celltrion, Domain Therapeutics, Lilly, Eupraxia, Ferring, Forte Biosciences, Fresenius Kabi, Gilead, Janssen, McKesson, Mirador Therapeutics, Pendopharm, Pfizer Inc, Prometheus Biosciences Inc, Roche, Sanofi, Takeda, Tillotts Pharma; speaker fees: AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, Bristol Myers Squibb, Eli Lilly, Ferring, Fresenius Kabi, Janssen, Merck, Organon, Pendopharm, Pfizer Inc, Sanofi, Takeda and Tillotts Pharma; royalties: Springer Publishing; research support: AbbVie, Lilly, Ferring, Pfizer Inc.
IB consulting and lecture fees: AbbVie, Amgen, Biogen, Celgene/BMS, GmbH, Celltrion, Falk Foundation, Fresenius Kabi, Galapagos, Janssen‐Cilag, Lilly, Merck, Pfizer Inc, Pharmacosmos, Takeda, Tillotts.
AAf consulting fees: AbbVie, Bristol Myers Squibb, Lilly, Janssen, Pfizer Inc, Sanofi, Takeda; speaker fees: AbbVie, Bristol Myers Squibb, Lilly, Janssen, Pfizer Inc, Takeda; grant/research support: AbbVie, Janssen, Lilly, Pfizer Inc, Takeda; co-founder/board member of Scrubs & Heels Foundation.
PS consulting fees: Janssen, PRO.MED.CS Praha a.s and URGO; speaker fees: Polpharma and PRO.MED.CS Praha a.s.
MG, KL employees of Pfizer AG and shareholders of Pfizer Inc.
MKe employee at time of analysis and shareholder of Pfizer Inc.
MKu, CZ, DB, JCW employees and shareholders of Pfizer Inc.
MS employee of Pfizer Inc.
SD lecture/speaker fees\: AbbVie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer Inc, Takeda; consultancy/advisory fees: AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead Sciences, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, Pfizer Inc, Roche, Sandoz, Takeda, TiGenix, UCB, Vifor; directorship/ownership: Gastroenterology and Endoscopy.
DTR grant support: Takeda, Pfizer Inc; consulting fees: AbbVie, Abivax SA, Altrubio, Athos Therapeutics Inc, Bristol Myers Squibb, Celltrion, Connect BioPharma, Lilly, Genentech (Roche) Inc., Iterative Health, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer Inc, Sanofi, Spyre, Takeda, Vedanta Biosciences, Ventyx.

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine IBD

Submission format

Abstract

Session

Looking at the small details: Lessons from sub-studies of clinical trials in IBD

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Management of early-invasive (T1) colorectal cancer

Alexandra Langers, Jurjen J. Boonstra, James Hardwick

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

With the introduction of population-based screening programs in several countries, the proportion of patients diagnosed with early invasive colorectal cancer (T1 CRC) has been vastly increasing. There are several major challenges in clinical management of this patient group, resulting in significant practice variations among physicians.

This online course covers the most relevant aspects of clinical management of T1 CRC patients, and provides an overview of latest insights and current knowledge gaps. To facilitate the learning process, several questions on real-life patient cases have been included in which learners can bring the acquired knowledge directly into practice.

Learning objectives

  • To systematically assess colorectal lesions and identify those suspicious for submucosally invasive (T1) cancer
  • To learn about local resection techniques for T1 colorectal cancer
  • To gain insight into histological assessment of local en bloc resection specimens of T1 colorectal cancer
  • To be aware of considerations from the oncological and patient perspective in therapeutic decision making after local treatment for T1 colorectal cancer

Target audience

This course is suitable for gastroenterologists, surgeons, pathologists, nurses and any other healthcare professionals interested in, or actively involved in clinical management of T1 CRC patients. 

This course was developed by Alexandra M.J. Langers, Jurjen J. Boonstra, James C.H. Hardwick, Richard (H.) Dang et al. in receipt of an Activity Grant from UEG.

Reviewed & updated December 2022

Event

Management of early-invasive (T1) colorectal cancer

Topics

Digestive Oncology

Accreditation status

accredited

Duration

1 hour

Published

2020

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

UEG Podcast Episode
Journal Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Katarzyna Pawlak 1, Laurent Goessens 2

Affiliations

1 Department Gastroenterology, Endoscopy Unit, Hospital of the Ministry of Interior and Administration, Szczecin, Poland

2 Centre Hospitalier de Mouscron, Belgium

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Topics

IBD

Published

2022

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Joram Mooiweer 1, Sajid Anwar 1, Nathan Ribeiro 1, Sebo Withoff 1, Iris Jonkers 1

Affiliations

1 UMCG, Groningen, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Celiac disease (CeD) is characterized by villous atrophy, crypt hyperplasia, and chronic intestinal inflammation. Gluten-driven immune activation ultimately leads to the activation of CD8⁺ intraepithelial lymphocytes (IELs), which target the epithelium and contribute to villous atrophy. However, the precise immune–epithelial mechanisms underlying epithelial remodeling remain incompletely understood.

Aims & Methods

To address this, we combined single-cell RNA sequencing of duodenal biopsies with an autologous organoid–IEL co-culture model established from matched patient and control small intestinal biopsies.

Results

Single-cell analysis of CeD biopsies revealed marked epithelial remodeling, with loss of mature enterocytes and expansion of transit-amplifying (TA) cells. These TA cells displayed an IFNγ-response signature and were predicted to interact with IELs, suggesting a link between IEL activity and epithelial stress remodeling in vivo. To test this functionally, we generated patient- and control-derived intestinal organoids and matched CD8αβ⁺TCRαβ⁺ IEL lines and studied their interactions in co-culture. Upon IL-15 and IL-21 stimulation, CeD-derived co-cultures showed increased epithelial cell death compared to controls together with elevated IFNγ secretion. RNA sequencing of co-cultured organoids demonstrated the emergence of TA-like epithelial cells with a IFNγ-associated transcriptional program, recapitulating the epithelial state observed in CeD biopsies. To determine whether epithelial IFNγ signaling was required, IFNGR1 was blocked or knocked out genetically in organoids. Both interventions reduced IEL-mediated epithelial cell death. To further define the role of IFNγ, organoids were stimulated with IFNγ in the absence of IELs. IFNγ exposure induced a similar IFNγ-stressed TA-like state, but did not increase apoptosis. Instead, prolonged IFNγ stimulation increased organoid growth, consistent with crypt hyperplasia. Accordingly, IFNGR1-deficient organoids did not display the IFNγ-induced increase in growth.

Conclusion

Together, these findings identify IFNγ as a central mediator of CeD epithelial pathology with a dual role: promoting epithelial injury in the context of IEL activation, while driving epithelial proliferation and crypt hyperplasia upon sustained exposure.

Disclosure

Iris Jonkers is consultant for Ipsomics

Event

UEG Week Barcelona 2026

Topics

Endoscopy Small Intestine & Nutrition Immunology

Submission format

Abstract

Session

From modern diagnostics to treatments in coeliac disease

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

UEG Poster
New
Audio / Video Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Ha Won Im 1, Seunghyun Jang 2,1, BYEONG GWAN KIM 1, Chang Min Park 1, Jong Pil Im 1, Sihyun Kim 1

Affiliations

1 Seoul National University College of Medicine, Seoul, Korea, Republic of

2 Seoul National University Graduate School, Seoul, Korea, Republic of

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Multimodal large language models (MLLMs) are increasingly being used in medicine, but their role in endoscopy remains insufficiently explored despite the field’s strong dependence on image-based lesion detection and morphological assessment.

Aims & Methods

We evaluated five leading commercial and open-source MLLMs for colonic polyp detection with localization and Paris classification, and compared their performance with that of gastroenterologists and endoscopy-naive internists using the Seoul National University Hospital polyp dataset (SNU-P; 40 polyps, 160 frames). Colonoscopic images were retrospectively collected between January 2023 and December 2024. All procedures were performed by board-certified gastroenterologists using standardized protocols, and annotations were independently reviewed and validated by experienced gastroenterologists. Cases with severe motion artifacts, inadequate bowel preparation (Boston Bowel Preparation Scale score <6), or no consensus reference label were excluded. Five MLLMs—GPT-5 (OpenAI API), Gemini-3-Flash (Vertex AI), Qwen3-VL-8B, Qwen3-VL-32B, and MedGemma-4B—were evaluated on two tasks: (1) colonic polyp detection with localization and (2) Paris classification, using three temporally consecutive frames per lesion. Performance on both tasks was assessed on SNU-P and compared with that of four non-endoscopy-trained general internists and three endoscopy-trained gastroenterologists.

Results

For Task 1, Gemini-3-Flash delivered the best performance among the MLLMs, achieving a frame-level balanced accuracy of 78.3% and a lesion-level localization success rate (PolypAny) of 90.0%, whereas gastroenterologists reached 92.9% and 93.1%, respectively (Table 1). For Task 2, GPT-5 demonstrated the strongest overall performance among the MLLMs, with an accuracy of 68.8%, a macro-F1 score of 0.674, and a Cohen’s kappa of 0.583, while gastroenterologists achieved 72.9%, 0.732, and 0.638, and general internists achieved 66.4%, 0.665, and 0.553, respectively (Table 1).

Table 1. Task 1 (colonic polyp detection with localization) and Task 2 (Paris classification) performance evaluated on the SNU-P dataset (40 polyps).


Task 1Task 2
ModelsFrame-levelPolyp-level
(95% CI)
Lesion-levelClass-wise recall
Bal AccSpecificitySensitivityPolypAnyAccMacro
F1
Cohen’s κIpIspIsIIa
MedGemma4B62.527.597.537.5 [24.2, 53.0]18.80.119-0.08300.6250.1250
Qwen3-VL
8B
78.887.57075.0 [59.8, 85.8]46.90.3540.292100.750.125
Qwen3-VL
32B
84.697.571.762.5 [47.0, 75.8]53.10.4530.3750.7500.50.875
GPT-586.29577.580.0 [65.2, 89.5]68.80.6740.5830.8750.750.3750.75
Gemini-3
flash
78.367.589.290.0 [76.9, 96.0]53.10.4730.3750.87500.50.75
General internist88.987.589.495.3 [90.2, 97.8]66.40.6650.5530.650.5310.6880.833
Gastroenterologist93.898.392.295.8 [89.8, 98.4]72.90.7320.6380.7670.6250.6670.889

Conclusion

General-purpose MLLMs showed performance close to that of clinicians in lesion detection and localization, but clinicians continued to outperform them overall in Paris classification. These findings indicate that current MLLMs may have a supportive role in lesion identification during endoscopic practice, whereas morphology classification remains a more demanding task that still requires specialist interpretation. Further prospective, multi-center studies with larger and more diverse endoscopic datasets are needed to validate the clinical utility of MLLMs and to improve their performance in morphology-based classification tasks such as Paris classification.

Conference

UEG Week Barcelona 2026

Topics

Colorectal

Submission format

Abstract

Session

Lower GI endoscopy: Preventing cancer (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

UEG Podcast Episode
UEG Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Mary Phillips, Leigh Donnelly

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Topics

Primary Care

Published

2025

More Like This:

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

LONG-TERM ETRASIMOD EFFICACY IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR BIOLOGIC/JAKI EXPERIENCE: 2-YEAR OUTCOMES FROM THE ELEVATE UC OLE

David T. Rubin David T. Rubin, Silvio Danese, John C. Woolcott, Diogo Branquinho, Michelle Segovia, Chuanbo Zang, Maria Kudela, Michael Keating, Krisztina Lazin, Martina Goetsch, Patryk Smolinski, Anita Afzali, Irina Blumenstein, Christopher Ma, Alessandro Armuzzi, Marla C. Dubinsky, Bruce E. Sands

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

UEG Journal Best Paper Award 2022 - Combining biologics and small molecules in IBD

Laurent Goessens Laurent Goessens, Katarzyna Pawlak

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

A DUAL ROLE FOR IFNG IN EPITHELIAL INJURY AND CRYPT HYPERPLASIA IN CELIAC DISEASE

Iris Jonkers Iris Jonkers, Sebo Withoff, Nathan Ribeiro, Sajid Anwar, Joram Mooiweer

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

CLINICIAN COMPARISON OF MULTIMODAL LARGE LANGUAGE MODELS FOR COLONIC POLYP DETECTION AND PARIS CLASSIFICATION

Sihyun Kim Sihyun Kim, Jong Pil Im, Chang Min Park, BYEONG GWAN KIM, Seunghyun Jang, Ha Won Im

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.